Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLT-008 in Patients Receiving Chemotherapy for Leukemia or Myelodysplasia
NCT01297543Phase 2Completed
- Sponsor
- Cellerant Therapeutics
- Start
- Mar 2011
- Primary completion
- Nov 2014
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CLT-008 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and 1 more (10 arms), sponsored by Cellerant Therapeutics. Primary endpoint: Incidence of serious adverse reactions at 43 days. Started Mar 2011; status: completed.
02
Drugs
CLT-008
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT01297543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01297543.